CART-EGFR-IL13Ra2

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameCART-EGFR-IL13Ra2

Drug Alias NameCART-EGFR-IL13Ra2CAR-T-EGFR-IL-13-Ra-2

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-IL13R

TargetsEpidermal growth factor receptor erbB1Interleukin 13 receptor

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Pennsylvania

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pennsylvania

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A